Prevalence of hyperlipidemia in psoriatic arthritis patients in Riyadh, Saudi Arabia

Article Figures & Data

Table 1

- Baseline hyperlipidemia status among PsA patients in relation to medical comorbidities.

Variables	Hyperlipidemia at the first visit		P-value
Variables	Yes	No	P-value
Age groups at the first visit (n=101)
<30 Years old	4 (23.5%)	13 (76.5%)	0.055
30-60 Years old	41 (47.1%)	46 (52.9%)
>60 Years old	3 (21.4%)	11 (78.6%)
Gender (n=101)
Male	28 (56%)	22 (44%)	0.005
Female	20 (29.4%)	48 (70.6%)	0.005
Diabetes mellitus (n=101)
Yes	19 (61.3%)	12 (38.7%)	0.010
No	29 (33.3%)	58 (66.7%)	0.010
Hypertension (n=101)
Yes	20 (57.1%)	15 (42.9%)	0.024
No	28 (33.7%)	55 (66.3%)	0.024
Ischemic heart diseases (n=101)
Yes	3 (42.9%)	4 (57.1%)	1.000
No	45 (40.5%)	66 (59.5%)	1.000
Other comorbidities (n=102)
Yes	22 (42.3%)	30 (57.7%)	0.851
No	26 (39.4%)	40 (60.6%)	0.851
Smoking status (n=99)
Yes	3 (75%)	1 (25%)	0.305
No	45 (40.2%)	67 (59.8%)	0.305
Statin use
Yes	31 (62%)	19 (38%)	<0.001
No	17 (25%)	51 (75%)	<0.001

Table 2

- Patients lipid profile results on the last visits.

Variables	First visit		Last visit		P-value
Variables	Normal	High	Normal	High	P-value
Cholesterol	115 (84.6%)	21 (15.4%)	97 (89.8%)	11 (10.2%)	0.167
Low-density lipoprotein	105 (82.7%)	22 (17.3%)	97 (92.4%)	8 (7.6%)	0.004
High-density lipoprotein	103 (81.1%)	24 (18.9%)	90 (84.1%)	17 (15.9%)	0.332
Triglycerides	114 (87.0%)	17 (13.0%)	94 (88.7%)	12 (11.3%)	1.00

Table 3

- Classes and duration of bDMARDs and cDMARDs taken by the patients (N=141).

Variables	n	%
bDMARDs drug class (first drug) (n=100)
Anti-TNF	87	87.0%
IL17	8	8.0%
IL23	2	2.0%
IL12 and IL 23	1	1.0%
Targeted synthetic DMARDs	2	2.0%
Duration of use of bDMARDs (first drug) (n=91)
<1 Year	11	12.1%
1-5 Years	63	69.2%
>5 Years	17	18.7%
bDMARDs class (second drug) (n=55)
Anti-TNF	18	32.7%
IL17	26	47.3%
IL23	7	12.7%
Targeted synthetic DMARDs	4	7.3%
Duration of use of bDMARDs (second drug (n=51)
<1 Year	13	25.5%
1-5 Years	35	68.6%
>5 Years	3	5.9%
bDMARDs class (third drug) (n=24)
Anti-TNF	5	20.8%
IL17	8	33.3%
IL23	5	20.8%
IL12 and IL 23	2	8.3%
Targeted synthetic DMARDs	4	16.7%
Duration of use of bDMARDs (third drug) (n=21)
<1 Year	9	42.9%
1-5 Years	12	57.1%
>5 Years	0	0%
cDMARDs (N=141)
None	55	39.0%
Methotrexate	82	58.2%
Hydroxychloroquine	1	0.7%
Sulphasalazine	3	2.1%
Duration of cDMARDs use (n=81)
<1 Year	4	4.9%
1-5 Years	52	64.2%
>5 Years	25	30.9%

TNF: tumor necrosis factor, IL: interleukin, b: biologic, c: conventional, DMARDs: Disease-modifying antirheumatic drugs

Table 4

- Comparison of hyperlipidemia at the last visit according to the type of medication used bDMARDs or cDMARDs.

Variables		Hyperlipidemia at the last visit		P-value
Variables		Yes	No	P-value
Use of a bDMARDs (n=101)	Yes (%)	24 (31.6%)	52 (68.4%)	0.317
Use of a bDMARDs (n=101)	No (%)	5 (20%)	20 (80%)	0.317
Patient used more than one bDMARDs (n=76)	Yes (%)	12 (27.9%)	31 (72.1%)	0.464
Patient used more than one bDMARDs (n=76)	No (%)	12 (36.4%)	21 (63.6%)	0.464
Disease-modifying antirheumatic drugs (cDMARDs) (n=101)	Yes (%)	21 (30%)	49 (70%)	0.813
Disease-modifying antirheumatic drugs (cDMARDs) (n=101)	No (%)	8 (25.8%)	23 (74.2%)	0.813
Patient used a bDMARDs and cDMARDs (n=94)	Yes (%)	16 (30.8%)	36 (69.2%)	1.000
Patient used a bDMARDs and cDMARDs (n=94)	No (%)	13 (31%)	29 (69%)	1.000

b: biologic, c: conventional, DMARDs: disease-modifying antirheumatic drugs